Home/ Stocks/ FATE

Fate Therapeutics, Inc.

FATE XNAS

$2.80 +0.29 (+11.68%) ▲ 15-min delayed

Open

$2.53

High

$2.88

Low

$2.48

Volume

4.02M

Market Cap

$290.23M

About Fate Therapeutics, Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 161 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$1.30M	$-31,213,000	$-0.26
FY 2025	$6.65M	$-136,315,000	$-1.15
Q3 2025	$1.74M	$-32,250,000	$-0.27
Q2 2025	$1.91M	$-34,070,000	$-0.29

Related Market News

No specific coverage for FATE yet. Check out our latest market news or earnings calendar.

Get FATE Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Fate Therapeutics, Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.